Hemab’s Upsized IPO Puts Rare-Bleeding Biotech in the Market’s Better Graces
Hemab prices bigger at the top, turning COAG into a real biotech demand test
By Erik Aronesty · Published May 1, 2026 · Hemab Therapeutics Holdings, Inc. · COAG
CAMBRIDGE, Mass., May 1, 2026 — Hemab Therapeutics did not just clear the market. The rare-bleeding biotech priced an upsized IPO at $18 a share for 16.75 million shares, lifting gross proceeds to about $301.5 million before any greenshoe. For a pre-revenue biotech coming public into a selective tape, that is the part that matters: investors were willing to fund more stock, at the top of the range, and do it behind a syndicate led by Goldman Sachs, Jefferies and Evercore ISI, with Wedbush PacGrow as lead manager.
The setup looked smaller only a day earlier. Hemab's latest amended filing showed a 15 million-share deal marketed at $16 to $18, implying roughly $270 million at the midpoint. The final print says the book tightened rather than drifted, which gives this deal more shape than the average clinical-stage biotech launch.
That demand is landing on a story with real clinical texture. Hemab's lead asset, sutacimig, won FDA Breakthrough Therapy designation in March for Glanzmann thrombasthenia, and the company had already reported Phase 2 data showing an estimated 87% reduction in annualized treated bleeding rate in the weekly dosing cohort ahead of a planned Phase 3 study. Hemab also has HMB-002 in Phase 1/2 for Von Willebrand disease, which helps explain why public investors were asked to underwrite a platform rather than a single readout.
The balance sheet was not empty going in. Hemab disclosed in its S-1 that it ended 2025 with $185.5 million of cash, cash equivalents and marketable securities, after a $157 million Series C financing last October that the company described as multifold oversubscribed. That gives Hemab more financial depth than many newly listed biotech peers, even if it also reported a 2025 net loss of $48.7 million and no product revenue.
What is still missing is the kind of explicit sponsorship that can make a biotech IPO feel pre-sold. In the public materials reviewed, Hemab did not pair the launch with a disclosed cornerstone order or concurrent private placement. That leaves the upsizing itself as the cleanest signal of demand. For IPO readers, that is enough to keep COAG on the screen: a sizable biotech deal, a credible bank group, and a lead program that has already pushed beyond generic promise into regulatory and late-stage positioning.